Literature DB >> 7378577

A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients.

G Merlini, J G Waldenström, S D Jayakar.   

Abstract

The effect of the presenting clinical features on survival time was evaluated in 173 patients of a population of 201 individuals with multiple myeloma observed at Malmö General Hospital during the 11-yr period 1960 to January 1, 1971. Complete follow-up was continued until December 1978. One-hundred and five of the patients came from the city of Malmö and constitute a complete nonselected myeloma population. Bivariate correlation and multivariate regression analyses showed that the survival (i.e., the prognosis) could be accurately predicted in IgG and pure Bence Jones myeloma patients from (A) serum creatinine level, (B) serum calcium level, and (C) bone marrow plasma cell percentage; and in IgA myeloma patients from (A) hemoglobin level, (B) serum calcium level, and (C) serum M-component level. The results were synthesized to produce a simple and reliable clinical staging system with three stages (i.e., risks of death). To facilitate the clinical application, multivariate regression equations were developed to optimally predict the prognosis, and graphs were constructed in order to make the staging of the myeloma patients easier and quicker. The comparison of the duration of survival between the three groups of staged patients confirmed the high reliability of the present staging system.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7378577

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

1.  The albumin and monoclonal protein ratio as prognostic marker for multiple myeloma in the era of novel agents.

Authors:  Katalin Kádár; Krisztina Wolf; Judit Tábori; István Karádi; Judit Várkonyi
Journal:  Pathol Oncol Res       Date:  2012-07       Impact factor: 3.201

2.  Bone marrow biopsy in monoclonal gammopathies: correlations between pathological findings and clinical data. The Cooperative Group for Study and Treatment of Multiple Myeloma.

Authors:  A Riccardi; G Ucci; R Luoni; A Castello; A Coci; U Magrini; E Ascari
Journal:  J Clin Pathol       Date:  1990-06       Impact factor: 3.411

3.  Prognostic factors in multiple myeloma: role of beta 2-microglobulin and thymidine kinase.

Authors:  H Diem; A Fateh-Moghadam; R Lamerz
Journal:  Clin Investig       Date:  1993-11

4.  Monoclonal gammopathies in the west of Ireland: a preliminary study.

Authors:  J M Greally; G O'Toole; H McCann; H Grimes; B O'Connor; G Solan; N Walsh; E Egan
Journal:  Ir J Med Sci       Date:  1985-03       Impact factor: 1.568

5.  Peptichemio induction therapy in myelomatosis.

Authors:  G Merlini; P G Gobbi; A Riccardi; G Riva; C Sardi; S Perugini
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

6.  [Analysis of prognostic factors in plasmacytoma].

Authors:  W Gassmann; T Haferlach; N Schmitz; W Kayser; H H Euler; J Drews; H Löffler
Journal:  Klin Wochenschr       Date:  1984-10-01

7.  Association between diffuse idiopathic skeletal hyperostosis and multiple myeloma.

Authors:  P N Scutellari; C Orzincolo; G Castaldi
Journal:  Skeletal Radiol       Date:  1995-10       Impact factor: 2.199

8.  Spectrum of monoclonal gammapathies in Andhra Pradesh.

Authors:  T Malati; B Yadagiri; D M Krishna; V Shantaram; D Raghunadharao; K Subbarao
Journal:  Indian J Clin Biochem       Date:  2001-01

9.  Prognostic factors and classification in multiple myeloma.

Authors:  J F San Miguel; J Sànchez; M Gonzalez
Journal:  Br J Cancer       Date:  1989-01       Impact factor: 7.640

10.  Is the International Staging System superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant.

Authors:  P N Hari; M-J Zhang; V Roy; W S Pérez; A Bashey; L B To; G Elfenbein; C O Freytes; R P Gale; J Gibson; R A Kyle; H M Lazarus; P L McCarthy; G A Milone; S Pavlovsky; D E Reece; G Schiller; J Vela-Ojeda; D Weisdorf; D Vesole
Journal:  Leukemia       Date:  2009-03-26       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.